Polaryx Therapeutics, Inc. (PLYX)
NCM · Healthcare · Biotechnology
$2.01
+1.01%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$100.2M
Shares Outstanding
49.8M
Exchange
NCM
Currency
USD
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (974K) | (911K) | (2.0M) | (1.4M) |
| Net Income | (1.4M) | (1.5M) | (2.5M) | (1.4M) |
| Diluted EPS | $-0.03 | N/A | $-0.05 | $-0.03 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | (3.8M) | (4.4M) | (7.8M) |
| Net Income | (3.8M) | (30.4M) | (9.0M) |
| Diluted EPS | $-0.08 | $-0.64 | N/A |